Theravance Biopharma, Inc. financial data

Symbol
TBPH on Nasdaq
Industry
Pharmaceutical Preparations
Location
Ugland House, South Church Street, George Town, Grand Cayman, Cayman Islands
State of incorporation
Cayman Islands
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 532 % -42.4%
Return On Equity -24.8 % -45.4%
Return On Assets -13.4 % -18.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 49.2M shares -1.25%
Common Stock, Shares, Outstanding 49.2M shares -3.24%
Entity Public Float 459M USD -32.2%
Common Stock, Value, Issued 1K USD 0%
Weighted Average Number of Shares Outstanding, Basic 49M shares -6.35%
Weighted Average Number of Shares Outstanding, Diluted 49M shares -6.35%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 63.2M USD +15.9%
Research and Development Expense 36.5M USD -23.4%
Operating Income (Loss) -44M USD +34.6%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -40.7M USD +30.5%
Income Tax Expense (Benefit) 8.71M USD +93.6%
Net Income (Loss) Attributable to Parent -49.4M USD +13.4%
Earnings Per Share, Basic -1.01 USD/shares -6.32%
Earnings Per Share, Diluted -1.01 USD/shares -6.32%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 23.4M USD -67.4%
Assets, Current 116M USD -28%
Property, Plant and Equipment, Net 7.79M USD -16.2%
Operating Lease, Right-of-Use Asset 29.3M USD -21.9%
Other Assets, Noncurrent 7.47M USD -25.3%
Assets 356M USD -13.9%
Accounts Payable, Current 1.45M USD -38.6%
Employee-related Liabilities, Current 7.84M USD +19.2%
Contract with Customer, Liability, Current 24K USD 0%
Liabilities, Current 23.4M USD -7.62%
Contract with Customer, Liability, Noncurrent 175K USD -12.1%
Operating Lease, Liability, Noncurrent 40.8M USD -0.81%
Other Liabilities, Noncurrent 4.98M USD -35.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax 50K USD
Retained Earnings (Accumulated Deficit) -950M USD -5.49%
Stockholders' Equity Attributable to Parent 186M USD -24.6%
Liabilities and Equity 356M USD -13.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.02M USD +90.9%
Net Cash Provided by (Used in) Financing Activities -1.72M USD +96.9%
Net Cash Provided by (Used in) Investing Activities 17M USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 49.2M shares -3.24%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 14.3M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 24.2M USD -66.6%
Interest Paid, Excluding Capitalized Interest, Operating Activities 4.61M USD -67.9%
Deferred Tax Assets, Valuation Allowance 430M USD +1.78%
Deferred Tax Assets, Gross 447M USD +1.49%
Operating Lease, Liability 49.2M USD -5.75%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -49.1M USD +14%
Lessee, Operating Lease, Liability, to be Paid 66.1M USD -20%
Property, Plant and Equipment, Gross 30.7M USD -31.4%
Operating Lease, Liability, Current 4.2M USD -56.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 10.9M USD +2.98%
Lessee, Operating Lease, Liability, to be Paid, Year One 3.9M USD -60.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Deferred Income Tax Expense (Benefit) -513K USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 10.1M USD -53.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 11.2M USD +3.42%
Deferred Tax Assets, Operating Loss Carryforwards 153M USD +8.15%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 230K shares 0%
Unrecognized Tax Benefits 79.5M USD +4.57%
Lessee, Operating Lease, Liability, to be Paid, Year Four 11.5M USD +3%
Additional Paid in Capital 1.14B USD -0.99%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 17.4M USD -5.3%
Share-based Payment Arrangement, Expense 21.4M USD -19.3%
Interest Expense 2.43M USD -49.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%